ADCT at a glance
ADC Therapeutics SA (ADCT, SEC CIK 1771910) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as July 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ADC Therapeutics SA (ADCT) reported revenue of $81.4 million (up 14.9% from FY2024) and a net loss of $142.6 million. Diluted EPS was -$1.12.
- As of June 30, 2026, 20 institutional investment managers tracked by SignalX reported holding ADC Therapeutics SA (ADCT) shares worth $26.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $81.4M
- +14.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $26.3M · −1 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 7.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Total revenue $19.248M, up 2.2% YoY from $18.839M
- Product revenue $18.634M, up 3.0% YoY from $18.085M on higher pricing
- Operating loss $25.414M, down 42.4% YoY from $44.147M
- Net loss $16.565M, down 70.8% YoY from $56.646M
- LOTIS-5 regulatory concerns over Grade 5 events and marginal treatment benefit; restructuring reduces workforce approximately 17%
Risk Factors
- New regulatory risk: FDA raised substantial concerns over LOTIS-5’s benefit-risk profile after increased Grade 5 adverse events and marginal treatment benefit
- Most material update: FDA or foreign regulators may require an additional confirmatory trial, delaying approval and consuming significant resources
- Compliance risk: ZYNLONTA’s accelerated 3L+ DLBCL approval could be withdrawn if LOTIS-5 fails to verify clinical benefit
- Near-term commercial risk: LOTIS-5 results could reduce ZYNLONTA sales and impair enrollment in other ZYNLONTA trials
AI summary of the ADCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Standard Regulation FD disclaimer language accompanying an investor disclosure
- No substantive business, financial, or operational update in the provided excerpt
Item 2.02: Results of Operations and Financial Condition
- Section contains only standard non-incorporation language
- No fiscal 2026 operating results or financial metrics provided in the excerpt
Item EX-99.1: Item EX-99.1
- Q2 product revenue $18.6M, up from $18.1M; growth driven by higher pricing rather than underlying volume
- FDA raised substantial LOTIS-5 benefit-risk concerns tied to Grade 5 events and marginal benefit, delaying the full-approval path
Item 5.02: Departure/Appointment of Directors or Principal Officers
- One-time retention awards approved for CEO, CFO, and CMO, signaling efforts to preserve executive continuity through June 30, 2027
- Cash awards total $2.91 million, payable around July 15, 2026 and repayable upon qualifying early departures
Item 7.01: Regulation FD Disclosure
- Reg FD disclosure furnished under Item 7.01, with Section 18 liability protections
- Content excluded from incorporation by reference into other SEC filings absent explicit reference
Item 8.01: Other Events
- Global workforce reduction of approximately 17% tied to expected completion of LOTIS-5 and LOTIS-7 trials
- Annualized cost savings estimated at approximately $10 million, supporting cash preservation
Item EX-99.1: Item EX-99.1
- 17% workforce reduction targets approximately $10 million in annualized savings, improving flexibility but reducing organizational capacity
- Approximately $3 million in pre-tax severance charges, mostly recognized in Q2 2026
AI summaries of ADCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ADCT
Don't miss the next ADCT filing
- Alerts as it files. A push when ADCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ADCT, by share count.
- Ask anything. An AI agent that reads every ADCT filing and answers with sources.
ADCT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Zaki Mohamed | A | Jun 30, 2026 | 213,900 | - |
| GRAHAM PETER J | A | Jun 30, 2026 | 221,100 | - |
| MALLIK AMEET | A | Jun 30, 2026 | 675,000 | - |
| Carmona Jose | A | Jun 30, 2026 | 203,700 | - |
| BIZZARI JEAN-PIERRE | F | Jun 3, 2026 | 12,600 | $3.08 |
| Monges Viviane | F | Jun 3, 2026 | 2,596 | $3.08 |
| Coughlin Timothy | F | Jun 3, 2026 | 12,600 | $3.08 |
| Sandor Victor | F | Jun 3, 2026 | 12,600 | $3.08 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $70.8M | $81.4M |
| Operating Income | - | -$130.7M | -$121.5M |
| Net Income | -$240.1M | -$157.8M | -$142.6M |
| Op. Margin | - | -184.4% | -149.3% |
| Net Margin | - | -222.8% | -175.3% |
| Balance Sheet | |||
| Total Assets | $354.8M | $322.0M | $323.1M |
| Equity | - | -$202.6M | -$185.8M |
| ROE | - | 77.9% | 76.7% |
| Per Share | |||
| EPS | $-2.94 | $-1.62 | $-1.12 |
| Cash Flow | |||
| Operating CF | - | -$123.8M | -$141.2M |
| CapEx | $3.2M | $867K | $264K |
Source: XBRL data in ADC Therapeutics SA (ADCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ADCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 20 | $26.3M |
| Q1 2026 | 21 | $84.2M |
| Q4 2025 | 19 | $61.9M |
| Q3 2025 | 18 | $65.1M |
| Q2 2025 | 17 | $39.5M |
| Q1 2025 | 15 | $13.7M |
| Q4 2024 | 13 | $6.7M |
| Q3 2024 | 11 | $9.8M |
- Citadel Advisors LLC+1.65M (+414%)
- BlackRock+769.3K (+12%)
- D.E. Shaw & Co+476.1K (+196%)
- AQR Capital Management+420.5K (+177%)
- Goldman Sachs Group+261.4K (+16%)
- Morgan Stanley−761.4K (-20%)
- JPMorgan Chase & Co−336.5K (-69%)
- Millennium Management−219.6K (-7%)
- Vanguard Portfolio Management LLC−136.2K (-13%)
- FMR LLC (Fidelity)−39.9K (-23%)
- Renaissance Technologies LLC−299.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 134 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ADCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 10-K | Mar 10, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 10, 2026 | - | Analysis | - |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| 4 | Feb 18, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ADCT SEC filings: frequently asked questions
Which institutions hold ADCT stock?
As of June 30, 2026, the largest ADC Therapeutics SA (ADCT) holders among the 13F filers tracked by SignalX were BlackRock ($7.5 million), Morgan Stanley ($3.3 million), Millennium Management ($3.1 million), Citadel Advisors LLC ($2.2 million), Goldman Sachs Group ($2.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ADCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ADC Therapeutics SA (ADCT) reported revenue of $81.4 million (up 14.9% from FY2024) and a net loss of $142.6 million. Diluted EPS was -$1.12. The figures come from the XBRL data in the 10-K.
What did ADCT report in its latest 8-K?
ADC Therapeutics SA (ADCT) filed an 8-K on August 13, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Standard Regulation FD disclaimer language accompanying an investor disclosure.
What are the latest ADCT SEC filings?
ADC Therapeutics SA (ADCT) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on July 2, 2026.
What is ADCT's SEC CIK number?
ADC Therapeutics SA (ADCT)'s SEC Central Index Key (CIK) is 1771910. EDGAR lists every ADCT filing under that number.
Ask anything about ADCT
The research agent reads ADCT's filings, financials, insider trades and 13F holders, then answers with sources.